Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 is a research paper published in Journal of Clinical Oncology (2007). On theSindex it has a DataRank of 0.900. It has been cited 402 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.900
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: CA13650
NCI NIH HHS
Grant: CA23318
NCI NIH HHS
Grant: CA31946
NCI NIH HHS
Grant: CA15488
NCI NIH HHS
Grant: CA16116
NCI NIH HHS
Grant: CA21115
NCI NIH HHS
Grant: CA66636
NCI NIH HHS
Grant: CA11083
NCI NIH HHS
Grant: CA49957
NCI NIH HHS
Grant: CA59307
Fields of Study
MeSH Terms
Additional file 1 of The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Additional file 1 of The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma